NYSE:STESteris Stock Price, Forecast & News

Steris' stock was trading at $145.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, STE stock has increased by 3.4% and is now trading at $150.16. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Steris in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Steris.

Steris is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Steris.

Steris PLC (NYSE:STE) announced its earnings results on Wednesday, May, 13th. The medical equipment provider reported $1.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.57 by $0.07. The medical equipment provider had revenue of $822.99 million for the quarter, compared to analyst estimates of $788.37 million. Steris had a net margin of 13.45% and a return on equity of 16.34%. During the same period last year, the business earned $1.53 EPS. View Steris' earnings history.

Steris announced a quarterly dividend on Wednesday, May 13th. Investors of record on Friday, June 12th will be given a dividend of $0.37 per share on Friday, June 26th. This represents a $1.48 annualized dividend and a yield of 0.99%. The ex-dividend date of this dividend is Thursday, June 11th. View Steris' dividend history.

3 Wall Street analysts have issued 12 month price targets for Steris' shares. Their forecasts range from $170.00 to $170.00. On average, they expect Steris' share price to reach $170.00 in the next twelve months. This suggests a possible upside of 13.2% from the stock's current price. View analysts' price targets for Steris.

News articles about STE stock have trended very negative recently, InfoTrie reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Steris earned a news impact score of -3.2 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Steris.

Steris saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 1,240,000 shares, a decline of 8.8% from the June 15th total of 1,360,000 shares. Based on an average daily trading volume, of 672,600 shares, the days-to-cover ratio is currently 1.8 days. Approximately 1.5% of the company's stock are sold short. View Steris' Current Options Chain.

Some companies that are related to Steris include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Steris investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Home Depot (HD), Mastercard (MA), AT&T (T), Abbott Laboratories (ABT), Cisco Systems (CSCO), Gilead Sciences (GILD) and Mcdonald's (MCD).

Steris trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."

Steris' stock is owned by many different institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.49%), West Coast Financial LLC (0.05%), State of Alaska Department of Revenue (0.05%), Carnegie Capital Asset Management LLC (0.04%), Mount Yale Investment Advisors LLC (0.03%) and Addenda Capital Inc. (0.01%). Company insiders that own Steris stock include Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Kathleen Bardwell, Loyal W Wilson, Michael B Wood, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard Martin Steeves, Walter M Rosebrough Jr and Walter M Rosebrough, Jr. View institutional ownership trends for Steris.

STE stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, West Coast Financial LLC, Fulton Bank N. A., Deane Retirement Strategies Inc., and Addenda Capital Inc.. Company insiders that have sold Steris company stock in the last year include Cary L Majors, Daniel A Carestio, John Adam Zangerle, Mohsen Sohi, Renato Tamaro, Richard Martin Steeves, and Walter M Rosebrough Jr. View insider buying and selling activity for Steris.

STE stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Mount Yale Investment Advisors LLC, Contravisory Investment Management Inc., Canandaigua National Corp, Whittier Trust Co. of Nevada Inc., Private Trust Co. NA, Forte Capital LLC ADV, and Park National Corp OH. View insider buying and selling activity for Steris.

Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of STE stock can currently be purchased for approximately $150.16.

Steris has a market capitalization of $12.76 billion and generates $3.03 billion in revenue each year. The medical equipment provider earns $407.61 million in net income (profit) each year or $5.64 on an earnings per share basis. Steris employs 13,000 workers across the globe.

The official website for Steris is www.steris.com.

Steris' mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider can be reached via phone at 353-1232-2000 or via email at [email protected]